Optimal current and future treatments for diabetic macular oedema

Eye

Volumn 24, Issue 3, 2010, Pages 428-434

  Blumenkranz, M S ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Diabetic retinopathy; Intravitreal steroids; Macula oedema; Phtocoagulation; VEGF

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; ILUVIEN; MAMMALIAN TARGET OF RAPAMYCIN; PEGAPTANIB; RANIBIZUMAB; RAPAMYCIN; RUBOXISTAURIN; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

CATARACTOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERANCE; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; GOLD STANDARD; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; LOW DRUG DOSE; OPTICAL COHERENCE TOMOGRAPHY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SUSTAINED DRUG RELEASE; THERAPY EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

EID: 77949445943     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.335     Document Type: Conference Paper

References (30)

1. Kempen JH, O'Colman BJ, Leske MC, Haffner SM, Klein R, Moss SE et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122(4): 552-563.
2. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: US, 2005-2050. Diabetes Care 2006; 29(9): 2114-2116.
3. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342(6): 381-389.
4. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18(12): 1450-1452.
5. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997; 29(5): 354-362.
6. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56(3): 794-814.
7. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103(11): 1820-1828.
8. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14(4): 223-232.
9. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study Group. Arch Ophthalmol 1985; 103(12): 1796-1806.
10. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125(4): 469-480.
11. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115(9): 1447-1449.
12. Blumenkranz MS, Yellachich D, Anderson DE, Wiltberger MW, Mordaunt D, Marcellino GO et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina 2006; 26(3): 370-376.
13. Jain A, Blumenkranz MS, Paulus Y, Wilberger MW, Andersen DE, Huie P et al. Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol 2008; 126(1): 78-86.
14. Muqit MM, Gray JC, Marcellino GR, Henson DB, Young LB, Charles SJ et al. Fundus autofluorescence and Fourierdomain optical coherence tomography imaging of 10 and millisecond Pascal retinal photocoagulation treatment. Br J Ophthalmol 2009; 93(4): 518-525.
15. Paulus YM, Jain A, Gariano RF, Stanzel BV, Marmor M, Blumenkranz MS et al. Healing of retinal photocoagulation lesions. Invest Ophthalmol Vis Sci 2008; 49(12): 5540-5545.
16. Foulds WS, Kaur C, Luu CD, Kek WK. A role for photoreceptors in retinal oedema and angiogenesis: an additional explanation for laser treatment?. Eye 2009; e-pub ahead of print 11 September 2009, doi:10.1038/eye.2009.173.
17. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109(5): 920-927.
18. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeurmer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22(3): 200-207.
19. Rudinsky CJ, Lavergne V, Katz D. Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Can J Ophthalmol 2009; 44(5): 587-593.
20. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009; 29(1): 46-51.
21. Kupperman BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125(3): 309-317.
22. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007; 18(3): 235-239.
23. Kane FE, Burden J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5(9): 1039-1046.
24. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009. Issue No. 7. Article no. CD007419.
25. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114(10): 1860-1867.
26. Cunningham Jr ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amizo DJ et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112(10): 1747-1757.
27. Ahmadi H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabael A, Azarmina M et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008; 246: 483-489.
28. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary end point (six months) results of ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116(11): 2175-2181.
29. PKC-DRS2 Group, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113(12): 2221-2230.
30. Dugel P. Sirolimus in the treatment of retinal diseases. mTOR inhibitors: a new class of therapeutics. Retina Today 2009; 4: 38-41.